A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has shown that interactions between tumor genes and microenvironment influence multiple myeloma treatment response in patients newly diagnosed undergoing combination treatments, including targeted immunotherapy. The study, published in in Nature…

White patients with diabetes and multiple myeloma have lower overall survival compared to Black patients with the same illnesses, according to a study published in Blood Advances. While research has shown that patients with myeloma and diabetes have poorer survival, this is the first to show racial differences in survival…

Originally Aired: May 22, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW In this proof-of-concept study, we established a novel liquid biopsy approach, MinimuMM-seq, enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics performed on bone marrow of multiple myeloma patients. CTCs harbored the same pathognomonic…

Scientists at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have initiated a first-in-human clinical trial for patients suffering from relapsed multiple myeloma using the immunotherapy REGN5459 with a 90 percent response rate when applying high doses of the drug. Multiple myeloma is an incurable cancer of plasma…

New research led by a team from the Maine Health Institute for Research, demonstrates that fatty acid binding protein 5—FABP5—known to be involved in fat transport and metabolism aids in the progression of multiple myeloma, the second most common form of adult blood cancer. The finding, published in eLife, could…

Data from a clinical trial published in The New England Journal of Medicine (NEJM) from researchers at Memorial Sloan Kettering Cancer Center (MSKCC) indicates that people with recurrent multiple myeloma may benefit from receiving chimeric antigen receptor (CAR) T therapy earlier in the course of their cancer. The Phase III…

New evidence supports the use of a three drug combo—carfilzomib, lenolidomide, and dexamethasone (KRd), for maintenance therapy after autologous stem cell transplantation in patients newly diagnosed with multiple myeloma. Maintenance therapy using these three drugs may improve progression-free survival as compared to single agent lenalidomide treatment. After almost 34 months…

A new multi-center study has found that therapies which engage T cells such as bispecific antibodies and CAR-T cell therapies exhibit the most durable response in patients with relapsed or refractory multiple myeloma following BCMA-directed CAR-T cell therapy. The study, published in the journal Blood,  was led by Sham Mailankody, MBBS, medical…

Mount Sinai researchers have for the first time identified genes that predict a good response to Selinexor, a new therapy for multiple myeloma, but one that can have serious side effects for some patients. Karyopharm’s selinexor (XPOVIO) is the first selective inhibitor of nuclear export to be approved for multiple myeloma.…

A five-drug combination therapy using existing drugs, combined with a stem cell transplant, has proven effective at extending the life of patients with an ultra-high risk form of multiple myeloma than those who received standard of care. The new research from investigators at the Institute of Cancer Research, London, and…

In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Now, researchers at Mount Sinai report in Science Advances that they have developed a new model to identify specific genes and genetic alterations responsible for never-before-defined subtypes of multiple myeloma. “The remarkable genetic…

The FDA has approved Bristol Myers Squibb’s and bluebird bio’s CAR-T cell therapy for treating the blood cancer multiple myeloma, the first cell-based gene therapy approved for this indication and is the first B-cell maturation antigen (BCMA)-directed therapy. Abecma (idecabtagene vicleucel) was approved for patients with multiple myeloma whose cancer…

Bristol Myers Squibb and bluebird bio’s autologous CAR T-cell therapy for multiple myeloma, idecabtagene vicleucel, succeeded in inducing at least a partial response in 73% of treated patients in a recent Phase II trial, with 33% having a complete response or achieving remission. Multiple myeloma is a cancer of the…

A new, targeted approach to the treatment of myeloma silences IRF4, a gene that allows myeloma stem cells and tumor cells to proliferate and survive. Past studies have shown that high IRF4 levels are associated with lower overall survival rates for patients with the disease. In the study “Selective antisense…

The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute said today they will partner to identify markers for a precursor disease to multiple myeloma, high-risk smoldering myeloma (SMM), and develop new treatment strategies designed to delay or prevent progression to active multiple myeloma. MMRF and Dana-Farber have launched a…